Abbott trims 2026 profit forecast on Exact deal hit, shares fall

Abbott Laboratories cut its full-year profit forecast, citing a 20 U.S. cent-per-share hit tied to its recent $23 billion acquisition of Exact Sciences. The guidance reduction pressured the stock, which fell more than 4% in premarket trading. The update reflects near-term earnings dilution from the deal despite the strategic rationale of the acquisition.

Analysis

Abbott Laboratories cut its full-year profit forecast, citing a 20 U.S. cent-per-share hit tied to its recent $23 billion acquisition of Exact Sciences. The guidance reduction pressured the stock, which fell more than 4% in premarket trading. The update reflects near-term earnings dilution from the deal despite the strategic rationale of the acquisition.